Events
ASCO 2025 Special Part 2! S3E5 The Oncology Journal Club
Welcome to Part 2 of the 2025 ASCO ASM Special of The Oncology Journal Club! Our Host Craig Underhill is joined by Dr Kate Clarke and Professor Christopher Jackson to unpack practice changing presentations from Chicago.
Adjuvant aumolertinib significantly improves disease-free survival after resection of EGFR-mutant NSCLC
- Epithelial–mesenchymal transition (EMT) and its role in acquired epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI) chemoresistance in non-small cell lung cancer (NSCLC)
- Study identifies tumour progression pattern as predictor of survival after first-line NSCLC therapy
- Which lung cancer subtypes are associated with different air pollutants?
Bowel cancer rates are declining in people over 50. But why are they going up in younger adults?
Suzanne Mahady, Monash University Bowel cancer is the fourth most common cancer in Australia, with more than 15,000 cases diagnosed…










